How a clinical-stage hemato-oncology company made a twice-doubted cancer mechanism visible enough for a sophisticated acquirer to assess

The mechanism became visible, the late-stage asset became legible, and Ipsen acquired Kartos for up to $1.75 billion, making navtemadlin its first hematology asset.

Challenge Making a differentiated MDM2/p53 mechanism, and complex late-stage data, visible enough to assess

Domain Myelofibrosis · MDM2–p53 pathway · hemato-oncology

Stage Clinical-stage · in-licensed from Amgen, advanced to registrational Phase 3, then acquired

Audience Medical & scientific audiences (HCPs, KOLs); investors & partners

Navtemadlin (KRT-232) is investigational and has not been approved by any regulatory agency.

MDM2 is the key negative regulator of p53 — MDM2 inhibits p53 transcriptional activity, transports it out of the nucleus, and tags it for proteasomal degradation; MDM2 overexpression in malignant cells drives proliferation, and MDM2 inhibitors such as navtemadlin restore p53 tumor-suppressor function.

MDM2 is the key negative regulator of p53 — the node navtemadlin was built to release.

The Science

Myelofibrosis begins with a driver mutation that activates JAK/STAT signaling and elevates MDM2, the ligase that marks the tumor suppressor p53 for degradation. The TP53 gene stays intact, but the p53 protein is suppressed and cannot clear the malignant clone.

Navtemadlin, a selective oral MDM2 inhibitor, blocks the MDM2–p53 interaction, freeing p53 to drive apoptosis in TP53 wild-type cells through pro-apoptotic BCL-2 modulation. It acts on a node ruxolitinib never reaches, clearing the clone standard treatment leaves behind.

Reactivated p53 induces pro-apoptotic Bcl-2 family proteins that overcome Bcl-XL and Mcl-1, forming Bax/Bak/Bok mitochondrial pores that release cytochrome C and activate caspase 9, driving apoptotic cell death. — The endpoint of reactivated p53 — pro-apoptotic Bcl-2 family proteins overcome Bcl-XL and Mcl-1, opening Bax/Bak/Bok mitochondrial pores that release cytochrome C and activate caspase 9 to drive cancer-cell death.

The Challenge

Navtemadlin's problem was not obscurity but doubt.

MDM2 inhibition carried two decades of failure. The rationale was always elegant: reactivate p53 where the gene is intact but suppressed. Turning that biology into a credible drug was where the class kept collapsing. A sophisticated evaluator would ask why this molecule differed from the ones that burned the field before. The answer lived in the mechanism and in dense, biomarker-selected trial data most people cannot read at a glance. To be assessed at its real value, the biology had to be seen, not just described.

The Work

Cognition made the mechanism seeable.

First, we separated navtemadlin from a doubted class by rendering what made it different: a 3D mechanism-of-action animation, and a freeze/thaw device that shows p53 suppression and reactivation as a visible state change, so TP53 wild-type selection reads as rationale, not caveat.

Second, we made complex late-stage evidence legible, tying each disease-modification biomarker to a single clinical claim across mechanism and pipeline visuals built for a congress-scale audience.

Third, we held one coherent scientific story across every audience that mattered, from KOLs to investors, through animation, interactive, and congress science. The biology stopped being described and started being seen.

Navtemadlin, a potent and selective investigational MDM2 inhibitor, binds MDM2 to release p53; at low concentrations it induced dose-dependent p53 activation, cell-cycle arrest via p21 and pro-apoptotic cell death in preclinical models. — Navtemadlin inhibits MDM2 to reactivate p53 — the switch that turns the whole mechanism on.

In myelofibrosis, navtemadlin-reactivated p53 drives p21-mediated cell-cycle arrest of malignant CD34+ cells, reducing the splenomegaly that defines the disease. — In myelofibrosis, reactivated p53 drives p21-mediated cell-cycle arrest of malignant CD34+ cells, reducing the splenomegaly that defines the disease.

The Outcome

Seen clearly, the asset read the way a late-stage program should.

The mechanism differentiated navtemadlin from a class the field had written off. The combination logic, navtemadlin layered on ruxolitinib rather than replacing it, framed a rational new standard. Ipsen acquired Kartos for up to $1.75 billion, making navtemadlin its first hematology asset and a late-stage addition to its oncology pipeline. For the roughly 40% of patients who never respond fully to standard of care, it points to a new option.

Up to $1.75B

Ipsen acquired Kartos — $450M upfront and up to $1.3B in milestones.

First in heme

Navtemadlin becomes Ipsen's first hematology asset and a late-stage addition to its oncology pipeline.

~40%

Of patients never respond fully to standard of care — the population a new option points to.

Navtemadlin (KRT-232) is investigational and has not been approved by any regulatory agency. Deal terms reflect Ipsen's announced acquisition of Kartos Therapeutics (June 29, 2026).

The takeaway

A late-stage asset is worth what an acquirer can see in it. When the value lives in a mechanism the field has learned to doubt, rendering that biology visible is what turns a molecule into something a buyer can assess and back.

References

1 BOREAS (NCT03662126): Mascarenhas JO, et al. Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study. Blood 2024;144(Suppl 1):1000. SVR35 15% vs 5% (BAT); ~48% bone marrow fibrosis reduction; ~82% mean CD34+ reduction at Week 24.
2 KRT-232-109 (NCT04485260): Mascarenhas J, et al. Phase 1b/2 add-on study, navtemadlin plus ruxolitinib. HemaSphere 2023 (EHA 2023): SVR35 and TSS50 each 32% at Week 24.
3 POIESIS (NCT06479135; EUCT 2023-504724-25-00): Vachhani P, et al. Future Oncology 2026;22(7):781–793. Registrational Phase 3 add-on design; co-primary SVR35 and TSS50 at 24 weeks; top-line expected 2027.
4 Mechanism: Nakatake M, et al. JAK2 V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene 2011. Review: MDM2 inhibitors in myeloid cancers. Leukemia 2026.
5 Deal: Ipsen to acquire Kartos Therapeutics, June 29, 2026 ($450M upfront; up to $1.3B milestones; up to $1.75B total; expected close end of Q3 2026).

Related proof

Making the science seeable, in other rooms.

See the capability →

CD388 mechanism of action — multi-contact blocking of viral neuraminidase to prevent influenza release

Antiviral · Investor Relations

Turning a pivotal readout into a value proposition the market could price.

Efzofitimod — structural rendering of the engineered Fc-fusion protein

Sarcoidosis · Science Value Articulation

Turning a missed endpoint into a focused, data-defined clinical case.

Have a mechanism the field has learned to doubt?

Start a conversation →

Explore

All case notes→ Mechanism Visualization→ Investor Relations→